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ABSTRACT
Objectives: No long-term clinical efficacy and safety study of resveratrol as adjuvant therapy along with gold standard therapy has been conducted 
in patients with essential hypertension. The aim of this study was to investigate the efficacy and safety of resveratrol as an adjuvant therapy in newly 
diagnosed hypertensive patients.
Methods: In this randomized active-controlled study, hypertensive patients (male/female) of 20-65 years aged were randomized (1:1) to receive 
telmisartan 20 mg or telmisartan 20 mg plus resveratrol 1 g daily for 12 months. Efficacy variables included a change in systolic and diastolic blood 
pressure (DBP) from baseline and were followed up for every 3 months. Treatment-emergent adverse events were assessed.
Results: A total of 60 hypertensive patients were analyzed (telmisartan [n=30] and telmisartan plus resveratrol [n=30]). Resveratrol as an adjuvant 
with telmisartan significantly reduced in systolic (p<0.001) and DBP (p<0.001) as compared to telmisartan monotherapy. Change in systolic and DBP 
from baseline was significantly higher in telmisartan plus resveratrol group than telmisartan (p<0.001) at all followed visits. Both the study drugs 
have similar safety profile and found well tolerable.
Conclusions: Resveratrol plus Telmisartan was found to be superior over telmisartan monotherapy in reducing systolic and DBP in newly diagnosed 
hypertensive patients. Both the study drugs were effective with comparable safety profile. Our study supports the long-term clinical efficacy and 
safety study of resveratrol along with gold standard therapy in essential hypertension.
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INTRODUCTION
In India, hypertension affected around 25-30% in urban and 10-15% 
in rural subjects, according to the World Health Organization health 
statistics 2012, the prevalence of hypertension in India was 23.1% 
in men and 22.6% in women in equal or more than 25 years age. The 
raised blood pressure (BP) was a high-risk condition that caused 
approximately 51% of death from strokes and 45% from coronary 
artery disease in India [1]. Prevalence and economic burden related to 
hypertension have been increasing and are projected to be continued 
to increase [2].
Hypertension is a risk factor for the development of atherosclerosis, 
although the mechanisms have not been well elucidated [3]. The 
most common side effect of currently available gold standard therapy 
(angiotensin-converting enzyme inhibitors and angiotensin II Type 1 
(AT1) receptor antagonists) is a cough (~9%), angioedema (~3/1000), 
hypokalemia, and hyperkalemia. The most common side effects of beta-
blockers and diuretics are depression, lower high-density lipoprotein, 
and raises triglycerides, hypoglycemia, rebound hypertension, glucose 
intolerance, increased uric acid, erectile dysfunction in men and dose-
related hypokalemia [4,5]. To manage hypertension effectively, often 
combination therapy and adjusting dose of gold standard therapy from 
low to high is required to prevent mortality. This may result in long-
term safety issues and reduce the financial burden to patients and their 
family. The agent that helps in controlling BP is the better options for 
management of hypertension. The combination treatment therapy 
may also slow down the natural disease progression and reduces the 
complications associated with hypertension. To prevent side effects 
and financial burden due to combination therapy and high dose of 
gold standard therapy, there is need of an effective adjuvant therapy 
which is free from side effects, cost-effective, and enhances the efficacy 
of current gold standard therapy without the need of switching to 
aggressive therapy. Furthermore, there is a need of adjuvant therapy 
which keeps us healthy and useful as prophylaxis for the patients with 
risk factor of cardiovascular disease.
Resveratrol is a stilbenoid type of natural phenol, and a phytoalexin 
produced naturally by several plants [6]. Resveratrol reduces 
oxidative stress, improves vascular function, attenuates high BP, 
and prevents cardiac hypertrophy [7]. Another pre-clinical study 
suggested that resveratrol prevents monocrotaline-induced pulmonary 
hypertension in rats. Resveratrol exerts anti-inflammatory, antioxidant, 
and antiproliferative effects in the pulmonary arteries, which 
may contribute to the prevention of pulmonary hypertension [8]. 
Resveratrol administration reduces metabolic disturbances and lowers 
BP in obese rats [9]. This indicates that the possible use of resveratrol 
in combination with current anti-hypertensive therapy as an adjuvant 
therapy would be effective in preventing and treating high BP. Short-
term clinical use of Resveratrol 1 g/daily (500 mg twice daily [BD]) was 
found to be effective in decreasing BP when compared to placebo after 
45 days [10]. Another 4 week clinical study (in 10 subjects) suggested 
that there was no change in BP after administration of resveratrol 
(1 g/daily) [11].
We hypothesized that resveratrol could be one of the adjuvant therapy 
along with gold standard anti-hypertensive therapy, which may lead to 
significantly improve the effectiveness of gold standard therapy in the 
management of hypertension and also decrease the financial burden 
to the patients along with good safety profile. Moreover, no long-
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term clinical efficacy and safety study of resveratrol in hypertension 
patient have been conducted. Based on the above facts, the proposed 
clinical study designed to evaluate efficacy and safety of Resveratrol, 
as adjuvants in patients with recently diagnosed with hypertensive 
patients who were stable on telmisartan monotherapy.
METHODS
A prospective, randomized, parallel, open-label, comparative, 
active-controlled clinical study was conducted at the single study 
center in India. From September 2014 to August 2015, 60 patients of 
either sex of 20-65 years who had stage I hypertension (systolic BP 
[SBP] 140-159 mmHg and diastolic BP [DBP] 90-99 mmHg), and stable 
on telmisartan 20 mg monotherapy were enrolled. Pregnant women, 
lactating mothers, history of severe heart disease, hepatic disease and 
renal dysfunction, willing to use other antioxidant supplementation 
rather than resveratrol, grapes allergy, the patient was receiving drug 
which affect BP, and regular alcoholics were excluded from this study. 
During the screening visit on the day, medical history was obtained; 
physical examination and laboratory investigations were performed. 
Medications considered necessary for the patient and which does 
not interact with the study medication were allowed. All patients 
were explained the procedure clearly and written informed consent 
from each participant was obtained before their participation in the 
study. The protocol was approved by Safety, Health and welfare Ethics 
Committee, registered under Drug controller general of India (Reg No: 
ECR/632/Inst/MH/2014). The study was conducted in compliance with 
the Ethical principles of Declaration of Helsinki; Good Clinical Practices 
guidelines issued by the Central Drugs Standard Control Organization, 
Ministry of Health, Government of India; Ethical guidelines for 
biomedical research on human participants, Indian Council of Medical 
Research, New Delhi; and International conference on harmonization of 
technical requirements for registration of pharmaceuticals for human 
use - guideline for good clinical practices. The trial was registered with 
Clinical Trial Registry-India before initiation of the study. Enrolled 
patients were randomized in 1:1 in 2 groups as per the computer 
generated sheet. The patients randomized in the interventional group 
(test group) were received telmisartan 20 mg once daily along with 
oral resveratrol 500 mg twice a day (a total of 1 g/daily). The patients 
randomized to control group were received only telmisartan 20 mg 
once daily. The treatment duration was 12 months for both the groups. 
Compliance to study drugs was assessed using pill count method at 
each assessment visit after dispending study drugs to patients.
Both systolic and DBP was assessed twice with 2 minutes apart after 
a 5-minutes rest in the sitting position, using an auscultatory method 
of measurement with a properly calibrated and validated mercury 
sphygmomanometer. Two measurements were made 2 minutes apart. 
SBP is the point at which the first of two or more sounds is heard 
(phase 1), and DBP is the point before the disappearance of sounds 
(phase 5). The mean of the two recordings was taken for analysis. Heart 
rate was measured for 1 minute in the 2-minute interval between BP 
measurements. Body temperature was measured by thermometer. 
BP (SBP and DBP) and heart rate were measured at baseline (before 
the start of study treatment), end of 3, 6, 9, and 12 months in both the 
treatment groups.
Statistical analysis
Based on a power of 80% and a type I error rate of alpha = 0.05 
(two-tailed), a sample size of at least 52 patients per group was required 
to detect a clinically significant difference of 08 mmHg in the change in 
BP (with standard deviation [SD] of 10.26 [12]) between both groups. 
Considering dropout rate of 15%, total sample size will be approx. 
60 patients (60 patients in each group). Categorical data were presented 
as absolute number/percentage of patients while quantitative data 
were presented as mean ± SD. Depending on the distribution of data 
appropriate parametric or non-parametric test was used to find p value. 
Unpaired “t”/Man-Whitney test was used to analyze the quantitative 
data for between group comparisons. Within-group comparison was 
performed using paired t-test or Wilcoxan test for quantitative data 
based on the distribution of data. Missing data were handled using Mean 
substitution or Last observation carried forward method. Chi-square 
test/fisher exact test was used to compare the categorical or qualitative 
data of both the treatment groups. Normality tests (KS and SW test) 
were used to detect distribution of data for numerical data. p<0.05 was 
considered as the statistical significant difference.
RESULTS
There was no patient dropout from each group during the study 
period. At the end of the study, totally 30 patients in each group 
(control and intervention group) completed the study and subjected to 
statistical analysis. A consort diagram is presented showing the flow of 
participants through the study (Fig. 1).
Demographic and clinical characteristic of patients of both the 
treatment groups were comparable (Table 1).
At the baseline, there was no significant difference between both groups 
regarding age, gender, body weight, duration of disease and smoking, 
systolic and DBP. The prevalence of hypertension in the family was also 
comparable in both the treatment groups (Table 1).
Before the start of study drug treatment (at baseline), SBP and DBP 
were comparable in both the treatment group. There was gradual 
reduction in blood SBP and DBP over a period of 12 months hours in 
both the treatment groups as observed from the reduction trend in the 
SBP and DBP from baseline (Table 2).
In both the treatment groups, reduction in SBP and DBP was statistically 
significant when compared to baseline (within group comparison). 
Between-groups comparison showed that reduction in SBP and DBP 
was significant greater in test group at 3, 6, 9, and 12 months when 
compared to control (p<0.005 at each time point) (Table 2).
There was a significant improvement in SBP and DBP in both the 
treatment groups from baseline. However, improvement in SBP and 
DBP at 3, 6, 9, and 12 months from baseline was significantly greater in 
test group as compared to control group (Table 3).
The difference between the treatments for the change in SBP and DBP 
from baseline was statistically significant (Table 3).
DISCUSSION
In this prospective, randomized, parallel, open-label, comparative, active 
controlled, single center clinical study, resveratrol as adjuvant therapy 
significantly decrease SBP and DBP in patients with hypertension. 
Table 1: Demographic and baseline clinical characteristics




Gender (male/female) 21/9 18/12 >0.05
Age (year) 39.7±3.6 44.0±3.10 >0.05
Height (Cm) 167.1±5.3 168.9±5.20 >0.05
Weight (Kg) 80.8±3.9 78.5±4.62 >0.05
Smoking
Yes 22 20 >0.05
No 8 10
Duration of disease (months) 1.8±0.9 1.7 0.7 >0.05
Family history of hypertension
Yes 24 23 >0.05
No 6 7
Control=telmisartan 20 mg, test=telmisartan 20 mg+resveratrol 500 mg twice 
daily. Values are expressed as Mean±standard deviation except for gender, 
family history of dyslipidemia and smoking. Absolute values are expressed 
for gender, family history of dyslipidemia and smoking. P value by unpaired 
t-test for continuous variables, fisher exact test for gender, family history of 
dyslipidemia and smoking
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prevents monocrotaline-induced pulmonary hypertension in rats. 
Resveratrol exerts anti-inflammatory, antioxidant, and antiproliferative 
effects in the pulmonary arteries, which may contribute to the 
prevention of pulmonary hypertension [8]. Long-term resveratrol 
administration reduces metabolic disturbances and lowers BP in 
obese rats [9]. Chronic resveratrol enhances endothelium-dependent 
relaxation in aorta of spontaneously hypertensive rats [11]. Resveratrol 
has a preventive effect on hypertension-induced cardiac hypertrophy 
in rats [13]. Moreover, our study results were also consistent with the 
previous clinical reports, short-term clinical use of resveratrol 1 g/daily 
(500 mg BD) was found to be effective in decreasing BP when compared 
to Placebo after 45 days [12]. Another 4 week clinical study (in 10 
Fig. 1: Flow of participants through the study
Table 2: Blood pressure (mmHg) at baseline and over the period 
of 12 months after study drug treatments
Parameters Control (n=30) Test (n=30) p
Baseline
SBP 151.7±8.3 156.0±8.14 >0.05
DBP 100.3±8.5 104.3±6.79 >0.05
End of 3 months
SBP 135.0±5.1* 131.0±5.48* <0.05
DBP 84.7±5.7* 82.0±4.07* <0.05
End of 6 months
SBP 127.7±7.3* 123.7±4.90* <0.05
DBP 83.7±4.9* 80.3±1.83* <0.05
End of 9 months
SBP 123.7±4.9* 120.3±1.83* <0.05
DBP 81.7±3.8* 79.0±3.05* <0.05
End of 12 months
SBP 123.0±4.7* 119.3±2.54* <0.05
DBP 81.0±3.1* 78.3±3.79* <0.05
Values are expressed as mean±standard deviation. *p<0.05 from baseline by 
paired t-test (within group comparison). Between-groups comparison was 
done using unpaired t-test, DBP: Diastolic blood pressure, SBP: Systolic blood 
pressure
Resveratrol as adjuvant therapy having acceptable safety profile and 
the most common adverse event is a gastrointestinal disturbance. 
Our study suggested that the addition of resveratrol to gold standard 
therapy of anti-hypertensive class of drug and significantly improve the 
efficacy of gold standard therapy, possibly due to synergistic action. The 
potential effect of resveratrol in the management of hypertension has 
been established in pre-clinical setting. In rodent model, resveratrol 
was effective in preventing obesity and oxidative stress and reducing 
the risk of hypertension and dyslipidemia in adult rats [10]. Resveratrol 
Table 3: Change in blood pressure (mmHg) from baseline to 3 
months, 6, 9 and 12 after study drug treatments
Parameters Control (n=30) Test (n=30) p
End of 3 months
SBP −16.7±8.8* −25.0±78.61* <0.05
DBP −15.7±7.3* −22.3±7.74* <0.05
End of 6 months
SBP −24.0±10.7* −32.3±9.71* <0.05
DBP −16.7±6.6* −24.0±7.70* <0.05
End of 9 months
SBP −28.0±8.9* −35.7±8.58* <0.05
DBP −18.7±7.3* −25.3±7.76* <0.05
End of 12 months
SBP −28.7±9.7* −36.7±7.58* <0.05
DBP −19.3±8.7* −26.0±7.70* <0.05
Values are expressed as mean±standard deviation. *p<0.05 from baseline by 
paired t-test (within group comparison). Between-groups comparison was 
done using unpaired t-test, DBP: Diastolic blood pressure, SBP: Systolic blood 
pressure
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subjects) suggested that there was no change in BP after administration 
of resveratrol (1 g, 1.5 g and 2 g/daily) [14].
We also observed that resveratrol as adjuvant therapy was found to 
be effective in improving SBP and DBP in patients with hypertension. 
Results of our study showed the combination of resveratrol and gold 
standard therapy of anti-hypertensive class of drug significantly 
improve SBP and DBP levels as compared to the monotherapy; this 
was possibly due to synergistic action. Our study results with respect 
to anti-hypertensive effect of resveratrol were consistent with previous 
report [12,14]. Our study support the long-term clinical efficacy 
and safety study of resveratrol along with gold standard therapy in 
hypertension patients and suggested synergistic effect of resveratrol 
when given along with gold standard therapy as adjuvant therapy in a 
clinical setting in the management of hypertension.
CONCLUSION
Resveratrol as an adjuvant therapy was found to be well tolerated and 
effective in hypertension. Both the study drugs have comparable safety 
profile and found well tolerable. Resveratrol plus telmisartan was found 
to be superior over telmisartan monotherapy in reducing SBP and DBP 
in patients with essential hypertension.
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